Citrate Metal Salt Endodontic Treatment Formulation Patent
Summary
USPTO granted patent US12605305B2 to Kunming Qingcheng Healthcare Tech LTD. on April 21, 2026, covering an application of citrate metal salt in endodontic treatment and its formulation. The patent claims use of lithium citrate, sodium citrate, potassium citrate, or magnesium citrate for removing smear layer in root canal procedures, co-formulated with a citrate metal salt-compatible single-chain cationic antimicrobial agent. The invention is classified under CPC codes A61K 6/52 and A61K 6/69, with 8 claims total. Filing date was July 19, 2021, under application number 18025339.
“The citrate metal salt is co-formulated with a citrate metal salt-compatible single-chain cationic antimicrobial agent, achieving results that are currently achieved only by alternating rinsing with EDTA-containing and sodium hypochlorite preparations in endodontic treatment.”
About this source
GovPing monitors USPTO Patent Grants - Pharma (A61K) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 22 changes logged to date.
What changed
USPTO issued patent grant US12605305B2 for a citrate metal salt formulation used in endodontic (root canal) treatment to Kunming Qingcheng Healthcare Tech LTD. The patent covers using lithium citrate, sodium citrate, potassium citrate, or magnesium citrate for smear layer removal, co-formulated with a compatible single-chain cationic antimicrobial agent. The granted patent comprises 8 claims under CPC classifications A61K 6/52 and A61K 6/69.
For competitors in dental/medical formulations, this patent creates an intellectual property barrier in the endodontic treatment space. Companies developing similar citrate-based root canal formulations or antimicrobial co-formulations may need to evaluate potential licensing needs or design-around strategies. The patent owner gains exclusive rights to the claimed formulations and methods in the United States.
Archived snapshot
Apr 22, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Application of citrate metal salt in endodontic treatment, and formulation obtained by preparation
Grant US12605305B2 Kind: B2 Apr 21, 2026
Assignee
Kunming Qingcheng Healthcare Tech LTD.
Inventors
Lei Zhang, Yu Sun, Kewang Lu, Yang Song, Yangfangyuan Long
Abstract
Provided are an application of a citrate metal salt in endodontic treatment, and a formulation obtained by preparation; said citrate metal salt is used for removing a tarnished layer, and the citrate metal salt is lithium citrate, sodium citrate, potassium citrate, or magnesium citrate. The citrate metal salt is co-formulated with a citrate metal salt-compatible single-chain cationic antimicrobial agent, achieving results that are currently achieved only by alternating rinsing with EDTA-containing and sodium hypochlorite preparations in endodontic treatment.
CPC Classifications
A61K 6/52 A61K 6/69
Filing Date
2021-07-19
Application No.
18025339
Claims
8
Related changes
Get daily alerts for USPTO Patent Grants - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.